BMS
Shire and BMS secure NICE recommendations for oncology drugs
July 27, 2016Research and Development, Sales and Marketing BMS, Baxalta, NICE, Oncaspar, Shire, Yervoy, opdivo
The National Institute for Health and Care Excellence (NICE) has issued final guidance recommending Shire’s Oncaspar (pegaspargase) and Bristol-Myers Squibb’s …
AbbVie and BMS partner for Rova-T, Opdivo, Yervoy cancer combo
July 26, 2016Manufacturing and Production, Research and Development AbbVie, BMS, Yervoy, opdivo, rova-t
AbbVie and Bristol-Myers Squibb have announced that they will collaborate on a clinical trial to test some of their leading …
CHMP issues positive opinion for Orencia Rheumatoid Arthritis treatment
July 25, 2016Manufacturing and Production, Sales and Marketing BMS, CHMP, Orencia, rheumatoid arthritis
Bristol-Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion of …
Bristol-Myers Squibb settle $30 million California kickback lawsuit
July 20, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, california, lawsuit
Bristol-Myers Squibb (BMS) has agreed to pay $30 million to the California Department of Insurance to settle an almost decade …
Bristol-Myers Squibb acquires Cormorant Pharmaceuticals in deal worth up to $425 million
July 6, 2016Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, cormorant
Bristol-Myers Squibb (NYSE: BMY) has announced that it has acquired all outstanding capital stock of Sweden-based Cormorant Pharmaceuticals, granting it …
Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb
June 21, 2016Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer
Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …
Nice backs BMS’ combination immunotherapy Opdivo, Yervoy to treat skin cancer
June 17, 2016Medical Communications, Research and Development, Sales and Marketing BMS, NICE, oncology, opdivo, regulation, skin cancer
The National Institute for Health and Care Excellence (Nice) has backed a combination of Bristol-Myers Squibb’s immunotherapy Opdivo (nivolumab) and …
Nice recommends three drugs to treat diabetes
May 25, 2016Research and Development, Sales and Marketing AstraZeneca, BMS, Boehringer Ingelheim, Eli Lilly, Janssen, NICE, diabetes
The National Institute for Health and Care Excellence (Nice) has backed three drugs for the treatment of type 2 diabetes. …
Multiple myeloma treatment from BMS and AbbVie scores EU approval
May 12, 2016Research and Development, Sales and Marketing AbbVie, BMS, EMA, EU, Empliciti, approval, bristl-myers squibb, elotuzumab, multiple myeloma
Bristol-Myers Squibb (NYSE: BMY) and AbbVie (NYSE: ABBV) have announced that the European Commission has approved Empliciti (elotuzumab) for the …
NICE backs BMS’ paclitaxel in ovarian cancer; drops Eli Lilly’s Gemzar, J&J’s Yondelis
April 27, 2016Research and Development, Sales and Marketing BMS, Eli Lilly, J&J, JJ, NICE, ovarian cancer, regulation
The National Institute for Health and Care Excellence (NICE) has backed Bristol-Myers Squibb’s paclitaxel as a treatment for ovarian cancer. …
Focus: Bristol-Myers Squibb’s wonder drug – Opdivo
April 20, 2016Research and Development, Sales and Marketing BMS, growth, immuno-oncology, opdivo, sales
By Anjali ShuklaNew data for Bristol-Myers Squibb’s (NYSE: BMY) Opdivo to treat head and neck cancer showed superior survival compared with …
EMA fast-tracks BMS multiple myeloma drug
February 1, 2016Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, EMA, Empliciti, myeloma
The EMA has recommended granting a marketing authorisation for Bristol Myers-Squibb and AbbVie’s immunotherapy Empliciti for the treatment of multiple myeloma. The …
FDA approves new uses for BMS’ Opdivo/Yervoy cancer combo
January 25, 2016Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilimumabm melanoma, nivolumab, opdivo, skin cancer
The FDA has granted Bristol Myers Squibb an expanded indication for its two-cancer drug regimen Opdivo and Yervoy, to treat …
NICE ‘yes’ for BMS skin cancer drug Opdivo
January 22, 2016Medical Communications, Sales and Marketing BMS, Bristol-Myers Squibb, NICE, melanoma, nivolumab, opdivo, skin cancer
NICE has approved Bristol-Myers Squibb’s skin cancer immunotherapy Opdivo (nivolumab) in final draft guidance as monotherapy for NHS patients in England …
ViiV Healthcare to acquire Bristol-Myers Squibb’s HIV pipeline drugs
December 18, 2015Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, HIV, ViiV, ViiV Healthcare
Specialist HIV company ViiV Healthcare has agreed deals worth up to $1.46 billion to purchase Bristol-Myers Squibb’s late stage HIV …
Latest content
Santen joins inaugural Global Summit for Eye Health as partner
